Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Its pharmaceutical name is afamelanotide. The molecule is a 13-amino-acid melanocortin analog with substitutions that make it more stable than native alpha-MSH, including norleucine at position 4 and D-phenylalanine at position 7. The approved drug form is SCENESSE, a bioresorbable 16 mg subcutaneous implant.

• This is important: the approved product is not a vial of powder for home injection. It is inserted by a trained healthcare professional and has a controlled-release pharmacokinetic profile.
• Classification: melanocortin receptor agonist, primarily discussed as an MC1R-focused pigmentation and photoprotection agent. It is related to Melanotan II, but it is not the same molecule. Melanotan II is cyclic, nonselective, and unapproved; Afamelanotide is linear, more MC1R-focused, and approved for a narrow medical indication.
• The FDA-approved afamelanotide/SCENESSE implant context is separate from unapproved Melanotan I research/cosmetic products. The approved product is a controlled-release implant for erythropoietic protoporphyria, not a generic tanning powder protocol.

• Afamelanotide binds predominantly to melanocortin-1 receptor (MC1R) on melanocytes. MC1R activation increases cyclic AMP signaling and stimulates eumelanin production.
• Eumelanin is the darker pigment associated with increased photoprotection compared with pheomelanin.
• For EPP, this does not cure the porphyrin pathway defect. Instead, it increases the skin pigment barrier and raises the amount of light exposure a patient can tolerate before phototoxic pain occurs.
• Patients are still advised to maintain sun and light protection measures.
• Compared with Melanotan II, afamelanotide is less defined by MC3R/MC4R central effects. This is why the libido, spontaneous erection, appetite, and severe nausea profile associated with MT-II does not carry over to Melanotan I as if the two were identical.
• MT1 primarily activates MC1R to increase eumelanin and photoprotection. This differs from Melanotan II, which has broader melanocortin activity and more libido/erectile effects. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Erythropoietic protoporphyria (EPP): The FDA-approved indication is to increase pain-free light exposure in adult patients with a history of phototoxic reactions from EPP. In the label-described trials, patients received 16 mg implants every two months and recorded sunlight exposure and phototoxic pain. SCENESSE-treated patients had more pain-free light exposure than vehicle-treated patients.
• Clinical trial synthesis: Randomized trials published in the medical literature found improved light tolerance and quality-of-life measures in EPP, with adverse events generally described as mild. The benefit is disease-specific, not a general “sunless tanning” intervention for healthy users.
• Vitiligo research: Afamelanotide has been studied as an adjunct to narrowband UVB phototherapy. A multicenter randomized trial in nonsegmental vitiligo reported faster and greater repigmentation when afamelanotide implants were combined with NB-UVB compared with NB-UVB alone. This is dermatology-supervised research and does not equal approval for cosmetic tanning.
• Gray-market risk: Unregulated alpha-MSH analog products sold online may be mislabeled, impure, contaminated, or different from the claimed compound. The clinical safety data for SCENESSE do not validate products sold as loose Melanotan I powder or nasal/injectable cosmetic kits.
• Afamelanotide has legitimate clinical evidence and approval for EPP phototoxicity reduction. That evidence does not validate unapproved powders, nasal products, or cosmetic tanning use. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: SCENESSE FDA label protocol for EPP [FDA/Approved/Label]; Route: Subcutaneous implant inserted by trained healthcare professional; Dose: 16 mg afamelanotide implant; Frequency: Every 2 months; Timing: Above anterior supra-iliac crest; Duration: Chronic labeled use per prescribing information; Status: Yes - FDA-approved label/product protocol for EPP only.
• Protocol 2: EPP clinical trial implant protocol [Clinical/Human Trial]; Route: Subcutaneous implant; Dose: 16 mg implant; Frequency: Every 2 months; Duration: 6 months in trial registry protocol; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 3: Historical afamelanotide SC PK/PD daily-dose study [Clinical/Human Trial]; Route: Subcutaneous injection; Dose: 0.08 mg/kg – 0.21 mg/kg; Frequency: Daily; Duration: 10 daily doses; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 4: Community acute pre-sun exposure protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.25 mg; Frequency: As-needed exposure protocol; Timing: ~30 minutes before sun exposure; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 5: Community loading and maintenance protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.25 mg – 0.5 mg loading; Maintenance 0.25 mg – 0.5 mg; Frequency: Daily loading; Then 1–2 times per week maintenance; Duration: Loading often around 10 days; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Protocol 6: Community higher loading/maintenance range [Community/Biohacker/Anecdotal]; Route: Subcutaneous injection; Dose: 0.5 mg – 1 mg; Frequency: Daily during loading; 2–3 times weekly maintenance; Duration: Loading often 1–2 weeks; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
• Approved-product dosing is implant-based and clinician-administered. Reconstituted powder dosing is not equivalent to Scenesse pharmacokinetics. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: about 2.5 to 3 days by half-life math for the approved implant PK, but repeated-dose steady state is not clinically meaningful with an every-two-month implant schedule.
• Half-life basis: the FDA label reports median Tmax of 36 hours and apparent half-life of about 15 hours after the controlled-release subcutaneous implant.
• Beginner translation: The drug level rises slowly from the implant, clears over days, and the pigmentation/photoprotection effect can last longer than measurable plasma drug. Do not confuse the half-life of the molecule with the duration of the skin-pigment effect.
• Practical interpretation: This estimate applies to the approved controlled-release implant. It does not extrapolate to unapproved injectable powders, nasal sprays, topical products, or other formulations marketed as Melanotan I. The implant formulation changes the PK. A free peptide injection could have different absorption and elimination, but robust public human PK for gray-market Melanotan I formulations is not available. If you're new, the correct comparison is not “Melanotan I vs Melanotan II dose”; It is “approved implant PK vs unverified product PK.”
• Implant release drives afamelanotide exposure. Bolus assumptions and calculator half-lives do not apply to the implant product. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• EPP care: Afamelanotide is used alongside, not instead of, sun and light protection. Protective clothing, avoidance strategy, and disease-specific clinician guidance remain central.
• Vitiligo research: The most clinically relevant stack is afamelanotide plus narrowband UVB phototherapy under dermatology supervision. This pairing is not casual tanning; It is a controlled phototherapy context where dose, timing, skin type, and lesion response are monitored. Avoid combining with Melanotan II or tanning-bed/high-UV behavior. The point of an MC1R-focused drug is not to justify unsafe UV exposure or to mask changing moles with darker pigment.
• Stacking with UV exposure is a safety issue, not just a tanning strategy. Photoprotection claims are no license for sunburn, tanning beds, or reduced sunscreen vigilance. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Label warnings include serious hypersensitivity reactions, including anaphylaxis, and the need for possible implant removal if a serious reaction occurs.
• Known severe hypersensitivity to afamelanotide or implant excipients is a contraindication.
• Skin monitoring is central. Afamelanotide can darken pre-existing nevi and ephelides because of its pharmacologic effect.
• The FDA label recommends a full-body skin examination twice yearly to monitor pre-existing and new pigmentary lesions.
• Common adverse reactions in the label include implant-site reactions, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory-tract infection, non-acute porphyria, and skin irritation.
• Pregnancy and lactation lack adequate human safety data.
• Monitor nevi, pigmentation changes, nausea, injection/implant reactions, and melanoma-risk context. Cosmetic tanning use can create behavioral risk by increasing UV exposure. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Dermatology: baseline and twice-yearly full-body skin examination; Track new, changing, asymmetric, bleeding, or rapidly darkening lesions. Standardized photos can help distinguish expected generalized pigmentation from concerning mole changes.
• EPP outcomes: patient diary of pain-free light exposure, phototoxic episodes, rescue behavior, quality of life, and seasonal exposure. EPP care may also require disease-specific monitoring such as porphyrin-related labs and liver assessment under specialist guidance.
• Implant safety: monitor insertion site for persistent pain, infection, extrusion, nodules, or allergic symptoms. Any throat tightness, wheezing, facial swelling, generalized hives, or systemic allergic reaction requires urgent medical evaluation.
• Dermatologic exams, baseline mole photos, EPP phototoxicity diaries in approved context, and sun-exposure behavior are useful. Any changing lesion warrants medical evaluation. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA: Approved as SCENESSE (afamelanotide) implant for adult patients with a history of phototoxic reactions from erythropoietic protoporphyria. Initial U.S. approval was in 2019; The current label describes the implant, professional administration, warnings, and PK.
• Not approved for cosmetic tanning: Afamelanotide approval for EPP does not authorize gray-market cosmetic tanning injections or powder kits. Products sold online as Melanotan I are not automatically pharmaceutical afamelanotide, and the guide’s sourcing/COA rules apply to them.
• Anti-doping: Afamelanotide is not the same regulatory category as unapproved Melanotan II. Competitive athletes should still verify status through GlobalDRO, USADA, or their sport governing body because product identity, prescription status, and jurisdiction matter.
• Afamelanotide/Scenesse is FDA-approved for a specific EPP indication. Melanotan I research powders or tanning-market products are not the same regulatory entity. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [G] FDA. SCENESSE (afamelanotide) implant, prescribing information, revised August 2024. Use: Melanotan I/afamelanotide indication, professional implant administration, 16 mg every-two-month dosing, hypersensitivity warning, skin monitoring, common adverse reactions, and PK (Tmax 36 hours; apparent half-life about 15 hours).

2. [A] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015. PMID:26132941. Use: EPP randomized-trial evidence for increased pain-free light exposure and quality-of-life context.

3. [B] Lim HW et al. Afamelanotide and narrowband UV-B phototherapy for the treatment of vitiligo: a randomized multicenter trial. JAMA Dermatology. 2015. PMID:25230094. Use: Dermatology-supervised vitiligo research context; not cosmetic tanning approval.

4. [F] Habbema L et al. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. International Journal of Dermatology. 2017. PMID:28266027. Use: Safety context for unregulated melanotan I/II products and cutaneous complications.

5. [C] Hadeler E et al. Evaluation of synthetic alpha-melanocyte-stimulating hormone analogs: an observational study of unregulated, online-available drugs. Journal of the American Academy of Dermatology. 2022. PMID:34333078. Use: Product-quality risk context for online alpha-MSH analogs.